The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable metastatic colorectal cancer (mCRC): A meta-analysis of individual patient data (IPD) from five randomized trials.
 
Chiara Cremolini
Honoraria - Amgen; Bayer; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Roche
Speakers' Bureau - SERVIER
Research Funding - Merck
Travel, Accommodations, Expenses - Roche; SERVIER
 
Carlotta Antoniotti
No Relationships to Disclose
 
Alexander Stein
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck KGaA; MSD; Roche
Speakers' Bureau - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
Thomas Gruenberger
Consulting or Advisory Role - Bristol-Myers Squibb; Humedics; Johnson & Johnson; Merck; MSD; Roche; SERVIER
Speakers' Bureau - Amgen; Humedics; Merck; Roche; SERVIER
Research Funding - Bristol-Myers Squibb; Humedics; Johnson & Johnson; Roche
Travel, Accommodations, Expenses - Humedics; Roche
 
Gianluca Masi
No Relationships to Disclose
 
Elena Ongaro
No Relationships to Disclose
 
Herbert Hurwitz
Employment - Genentech
 
Alfredo Falcone
Honoraria - Amgen; Lilly; Merck; Roche; SERVIER
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Merck; Roche; SERVIER
Research Funding - Amgen (Inst); Bayer (Inst); Merck (Inst); MSD (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck; Roche; SERVIER
 
Hans-Joachim Schmoll
Honoraria - Amgen; Roche
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche
Research Funding - Amgen; Roche
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Massimo Di Maio
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; Janssen; Mediolanum Farmaceutici; Merck Sharp & Dohme; Pfizer; Takeda
Consulting or Advisory Role - AstraZeneca; Eisai; Janssen; Mediolanum Farmaceutici; Merck Sharp & Dohme; Pfizer; Takeda
Research Funding - Tesaro (Inst)